Precision oncology diagnostics have advanced with NucleoBio and PreCheck Health Services collaborating to develop Prostac, a qPCR-based assay evaluating long noncoding RNA biomarkers for prostate cancer, particularly in men of African ancestry. Qiagen and Oxford Gene Technology partnered to integrate AI-powered bioinformatics for enhanced interpretation of next-generation sequencing panels in cancer. Additionally, Queen Mary University of London validated Ovatools, a personalized ovarian cancer risk score incorporating biochemical and demographic factors. These tools represent breakthroughs in early detection and precision diagnostics in oncology.